

Special Issue

Immunotherapy and Transplantation in the Era of Transplant Oncology

Message from the Guest Editors

Immune-checkpoint inhibitor (ICPI) therapies have shown excellent responses with tolerable side effects in the treatment of different cancers. However, our knowledge and experience in the use of immunotherapy in solid organ transplant recipients and candidates are limited. The use of immunotherapy in liver pre-transplant patients as bridging therapy, and as palliative therapy in post-transplant patients to treat cancer recurrence or second primary cancer, is an area of unmet need.

Transplant patients have been excluded from ICPI clinical trials due to concern for autograft rejection. In the last five years, retrospective studies and limited prospective trials have shown the possibility of using ICPIs in this patient population. This field of transplant oncology is currently being investigated. Our Special Issue will highlight the current state of the utilization of ICPI therapies in pre- and post-liver and other solid organ transplants, and will discuss the assessment of safety and response biomarkers.

Guest Editors

Dr. Maen Abdelrahim

Dr. Ala Abudayyeh

Dr. Abdullah Esmail

Deadline for manuscript submissions

closed (20 June 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/134617

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)